U.S. FDA Medical Device Cybersecurity Registration Requirements

Answer: The U.S. FDA cybersecurity requirements for medical devices are primarily based on the Medical Device Cybersecurity Guidance (updated in 2018). At registration, manufacturers must submit cybersecurity risk management documentation covering threat modeling, vulnerability analysis, security controls (such as encryption, authentication, and access control), a software bill of materials (SBOM), and a postmarket update plan. Product classification determines review intensity: Class II devices (such as infusion pumps) generally require a cybersecurity assessment, while Class III devices (such as pacemakers) require more comprehensive evidence. Technical files should cover secure design (such as the principle of least privilege), test reports (penetration testing and fuzz testing), and labeling with clear cybersecurity statements and update mechanisms. Security risk processes must be integrated into the quality system (QSR 820). Common errors include overlooking third-party component security, failing to provide an SBOM, or failing to explain encryption measures for remote maintenance. Manufacturers should prepare cybersecurity architecture diagrams, a vulnerability disclosure policy, and postmarket monitoring processes (such as continuous patch updates).

Published: July 8, 2026 09:00

Updated: July 8, 2026 09:00

This FAQ addresses priority questions companies need to assess in international medical device registration, documentation preparation, compliance pathways, and postmarket maintenance.

Key Summary

The U.S. FDA cybersecurity requirements for medical devices are primarily based on the Medical Device Cybersecurity Guidance (updated in 2018). At registration, cybersecurity risk management documentation must be submitted, including threat modeling, vulnerability analysis, security controls (such as encryption, authentication, and access control), a software bill of materials (SBOM), and a postmarket update plan. Product classification determines review intensity: Class II devices (such as infusion pumps) generally require a cybersecurity assessment, while Class III devices (such as pacemakers) require more comprehensive requirements.

Technical files should cover secure design (such as least privilege), test reports (penetration testing and fuzz testing), and labeling that clearly states cybersecurity claims and update mechanisms. Security risk processes must be integrated into the quality system (QSR 820). Common errors include overlooking third-party component security, failing to provide an SBOM, or failing to specify encryption measures for remote maintenance. Manufacturers should prepare cybersecurity architecture diagrams, a vulnerability disclosure policy, and postmarket monitoring processes (such as continuous patch updates).

Applicable Scenarios and Core Questions

Clients most often focus on how to demonstrate that their products meet FDA cybersecurity expectations and avoid 510(k) review delays or refusals. Core questions include: Which data must be submitted? How is the cybersecurity risk level determined? Do postmarket vulnerability patches require a new submission?

Registration Assessment Logic

FDA requirements are tiered based on whether a device has network connectivity, whether it stores patient data, and its security impact. Non-connected devices may be exempt. Connected devices must be classified as having major security risk or minor security risk. If product characteristics change (for example, a new remote service is added), the registration pathway must be reassessed.

Core Documentation and Evidence

• Cybersecurity risk management report, including threat analysis and mitigation measures
• Software bill of materials (SBOM) and third-party component vulnerability records
• Security test reports, such as penetration testing and authentication testing
• Design documentation, including security architecture and encryption implementation
• Cybersecurity statements in labeling, including update mechanisms and user responsibilities

Common Errors

• Overlooking known vulnerabilities in open-source components and failing to provide remediation plans
• Not distinguishing between premarket and postmarket security plans
• Lacking security validation for wireless communications such as Bluetooth and Wi-Fi
• Failing to clearly state in labeling the cybersecurity actions users must perform

Manufacturer Preparation Checklist

• Establish a cybersecurity expert team or engage external consultants
• Create secure development lifecycle (SDL) documentation
• Complete at least one independent third-party penetration test
• Develop a vulnerability disclosure policy and patch update process
• Compile an SBOM and link each component to vulnerability databases

AIMEILI Perspective

FDA cybersecurity review is not a standalone document exercise. It connects premarket design, evidence generation, labeling, and postmarket surveillance. Manufacturers should treat cybersecurity as part of the device safety and performance case, not as a late-stage attachment. Early gap assessment and a clear component-level vulnerability strategy can reduce 510(k) questions and postmarket enforcement risk.

Frequently Asked Follow-up Questions

Q: Is full source code required for submission?

A: Usually not, but security implementation details and testing evidence are required.

Q: How should vulnerabilities discovered after market release be handled?

A: If they represent a serious risk, manufacturers should notify FDA through a supplemental application or urgent notification, and release a patch immediately.

Continue Reading

Previous: FDA 510(k) Medical Device Registration Document Checklist?

Next: How to Prepare Clinical Evaluation Documentation for EU MDR?

Recommended Reading:

• FDA 510(k) Medical Device Registration Document Checklist?
• What Should Companies Prepare Before Australian TGA Medical Device Registration?
• Can Singapore HSA Medical Device Registration Reuse CE Documentation?
• What Core Documents Are Required for UAE MOHAP Medical Device Registration?
• Why Are Brazil ANVISA Medical Device Registration Timelines So Long?
• What Is the Difference Between a Vietnam Medical Device Import License and Registration Certificate?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supporting judgment.

Applicability boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal advice.

Source Note

Compiled from AIMEILI regulatory practice materials and public regulatory information. Specific projects should be based on the latest requirements of the target country regulatory authority and the product underlying documentation.